Novartis' Tabrecta is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer with a mutation that leads to MET exon 14 skipping.
GSK’s Zejula is the only oral monotherapy available as a first-line maintenance treatment for women regardless of BRCA mutational status, addressing a high unmet need in ovarian cancer.
As it moves into its second century in business, Upsher-Smith Labs is focusing on innovating and growing its product offerings while maintaining its high standards.
